Protein Design Labs regulatory update

PDLI has been issued a patent by the European Patent Office that the company said covers most humanized monoclonal antibodies, including the company's SMART antibody technology.

Specifically, patent number 0451216 covers humanized antibodies that contain both the mouse antibody binding site (complementarity determining regions - CDRs) transferred to a human antibody, and one or more amino acid substitutions from the mouse antibody into the humanized antibody framework. Such substitutions generally are required to give the antibodies adequate binding affinity for their target antigens. ...